menu search

Why is mainz biomed (mynz) stock moving today?

Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagnostic company shared results from a colorectal <...

November 1, 2023, 8:40 am

Nfl head coach pledges to pay forward support he received when facing cancer diagnosis

Washington Commanders’ Ron Rivera Recognized with the cancer support Community’s Founders Award for...

October 20, 2023, 6:41 pm

Bristol myers' (bmy) opdivo sc meets kidney cancer study goals

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kid...

October 20, 2023, 6:46 am

Iq-ai higlights use of subsidiary's software in brain cancer study

IQ-AI has highlighted a new study into a rare form of brain cancer that used subsidiary Imaging  Biometric's dynamic susceptibility contrast (DSC) ma...

October 18, 2023, 11:01 am

Sellas life sciences to present final data from phase 1/2 study of galinpepimut-s in combination with keytruda® (pembrolizumab) in patients with wt1+ platinum-resistant advanced ovarian cancer at the

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical b...

October 17, 2023, 8:45 am

Elucent announces new partnership with survivingbreastcancer.org

The Medical Device Company Will Sponsor the Educational Organization to Expand Its Reach to Patients, Families, Caregivers EDEN PRAIRIE, Minn., Oct. 1...

October 16, 2023, 9:02 pm

Tempest (tpst) up as first-line liver cancer study meets goals

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-...

October 12, 2023, 12:01 pm

Exact sciences schedules third quarter 2023 earnings call

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer...

October 9, 2023, 6:00 am

Exact sciences to present late-breaking data from pivotal blue-c study on next-generation cologuard at acg 2023

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of canc...

October 9, 2023, 5:58 am

Merck's (mrk) meets goal in muscle-invasive bladder cancer study

Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain pati...

October 6, 2023, 1:32 pm

Angle hails the latest breast cancer study

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy and cancer diagnostics specialist, has hailed a study that could change the way doctors monitor a...

October 3, 2023, 2:46 am

Nektar (nktr), cellular biomedicine join for lung cancer studies

Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC....

September 28, 2023, 9:01 am

Merck (mrk), eisai combo therapy fail two lung cancer studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung...

September 25, 2023, 1:32 pm

Astrazeneca's (azn) dato-dxd meets goal in breast cancer study

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with ...

September 25, 2023, 12:46 pm

Seagen's (sgen) combo drug meets goals in bladder cancer study

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metas...

September 25, 2023, 12:01 pm

Moleculin (mbrx) posts update from lung cancer study, stock up

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarco...

September 22, 2023, 9:01 am

Merck (mrk) keytruda cervical cancer sbla gets fda priority tag

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease....

September 21, 2023, 9:46 am

Bicycle (bcyc) to begin pivotal bladder cancer study, stock up

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to s...

September 12, 2023, 9:05 am

Gilead's (gild) trodelvy combo shows promise in nsclc study

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung ...

September 11, 2023, 12:46 pm

Lisata (lsta) up on positive updates for pancreatic cancer study

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer....

September 7, 2023, 2:16 pm


Search within

Pages Search Results: